Point mutations, often involving genes encoding proteins in the RAS signaling pathway, are frequently found in ERMS tumors whereas PAX3-FOXO1 (~60%) and PAX7-FOXO1 (~20%) gene fusions are hallmarks of ARMS tumors [10,11,12,13,14,15] and reviewed in [9,16]. Here, PAX3 is linked to alveolar rhabdomyosarcoma.